ML2006a4 - CAS 2943213-62-3

ML2006a4, an orally active SARS-CoV-2 main protease (Mpro) inhibitor, exhibits potent activity with an IC50 in the picomolar range. This compound is cell permeable and demonstrates antiviral efficacy by inhibiting the replication of SARS-CoV-2 in Huh7.5.1-ACE2-TMPRSS2 (Huh7.5.1++) cells at picomolar concentrations [1].

SARS-CoV

Microbiology/Virology

2943213-62-3

C30H44F3N5O6

627.7

C(N[C@@H](C[C@H]1C(=O)NCCC1)C(C(=O)N2CC(C)(C)C2)=O)(=O)[C@@H]3[C@@]4([C@@](C4(C)C)(CN3C([C@@H](NC(C(F)(F)F)=O)[C@](C)(C)C)=O)[H])[H]

-20°C

Ice Packs

Small Compound